Drugs / CP105F
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03857256 Comparator | May 2019 → Aug 2021 | hyperlipidemia | Montreal Heart Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CP105F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03857256 ↗ |
| Known as | Oat beta-glucan | “CP105F (Oat beta-glucan) 1.5g (1 tablet of 0.5g TID) for 12 weeks.” NCT03857256 ↗ |